Cardiovascular Disease Risk Assessment

Policy Number: AHS – G2050 – Cardiovascular Disease Risk Assessment

Prior Policy Name and Number, as applicable:
1. AHS – G2010 – Lipid Panels
2. AHS – G2050 – Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
3. AHS – G2053 – Cardiovascular Risk Panels
4. AHS – G2106 – Measurement of Serum Intermediate Density Lipoproteins
5. AHS – M2082 – Measurement of Lipoprotein, Associated Phospholipase A2
6. AHS – G2104 – Measurement of Long-Chain Omega-3 Fatty Acids
7. AHS – G2096 – Homocysteine Testing
8. AHS – M2090 – Genotyping for 9P21 Single Nucleotide Polymorphisms
9. AHS – M2102 – KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy
10. AHS – M2064 – Genetic Expression to Predict Coronary Artery Disease

Policy Revision Date: 03/09/2022

I. Policy Description

Cardiovascular risk assessment comprises the means and processes to predict the probability of developing a cardiovascular disease. These are a group of tests and health factors that have been proven to indicate a person's chance of having a cardiovascular event such as a heart attack or stroke.

Tests typically used to assess cardiovascular risk include, lipid profiles or panels, biomarkers, and cardiovascular risk panels.

II. Related Policies

<table>
<thead>
<tr>
<th>Policy Number</th>
<th>Policy Title</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
III. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in Section VII of this policy document.

Coverage Criteria 1, regarding lipid panels, is only intended for adult (18 years or older) patients.

1) Lipid Panel

a) Measurement of total cholesterol, HDL-C, LDL-C and triglycerides as part of an assessment of cardiovascular risk factors MEETS COVERAGE CRITERIA for any of the following:
   i) Every 4 to 6 years in patients ages 18 to 79 years.
   ii) Annually for patients at increased risk for cardiovascular disease as defined by 2013 ACC/AHA Pooled Cohort Equations (PCEs) to calculate 10-year risk of CVD events (see Note 1).

b) A lipid panel MEETS COVERAGE CRITERIA when evaluating an individual at increased risk of dyslipidemia due to any of the following conditions:
   i) Nephrotic Syndrome
   ii) Hypothyroidism
   iii) Hyperthyroidism
   iv) Pancreatitis
   v) Diabetes
   vi) Chronic Kidney Disease
   vii) Cushing Syndrome
   viii) Pregnancy
   ix) Cholestatic Liver Disease
   x) Lipid metabolism disorders, such as Gaucher disease in adults

c) Before beginning statin therapy, a lipid panel MEETS COVERAGE CRITERIA for establishing baseline levels for monitoring therapy.

d) For individuals receiving statin therapy, lipid panel testing MEETS COVERAGE CRITERIA up to every four to twelve weeks after initiation or change of therapy. Subsequently, annual lipid panel testing is considered medically necessary for individuals receiving statin therapy.
e) Lipid panel testing **MEETS COVERAGE CRITERIA** for individuals on a long-term drug therapy that requires lipid monitoring, including but not limited to, Accutane and anti-psychotics.

f) A lipid panel **MEETS COVERAGE CRITERIA** for any of the following when evaluating and managing an individual diagnosed with HIV and receiving antiretroviral therapy (ART):
   i) Prior to initiating ART (baseline)
   ii) Within one to three months after starting or modifying ART and every 6 to 12 months thereafter

2) Measurement of apolipoprotein B (apoB) **MEETS COVERAGE CRITERIA** for individuals with one of the following:
   a) Hypertriglyceridemia
   b) Diabetes mellitus
   c) Obesity or metabolic syndrome
   d) Other dyslipidemias (such as very low LDL-C)
   e) On lipid therapy
   f) To facilitate diagnosis of Familial Dysbetalipoproteinemia and Familial Combined Hyperlipidemia

3) Measurement of lipoprotein a (Lp(a)) **MEETS COVERAGE CRITERIA** in adult individuals with one of the following:
   a) Family history of first-degree relatives with premature atherosclerotic cardiovascular disease (ASCVD) (less than 55 years of age in men; less than 65 years of age in women) or elevated Lp(a)
   b) Individuals with premature ASCVD (less than 55 years of age in men; less than 65 years of age in women), particularly in the absence of traditional risk factors
   c) Individuals with primary severe hypercholesterolemia (LDL-C greater than or equal to 190 mg/dL) or suspected familial hypercholesterolemia (FH)
   d) Individuals at very high risk of ASCVD to better define those who are more likely to benefit from PCSK9 inhibitor therapy.

4) High-sensitivity C-Reactive Protein (hs-CRP)
   a) Testing for high-sensitivity C-reactive protein (hs-CRP) **MEETS COVERAGE CRITERIA** if, after quantitative risk assessment using ACC/AHA Pooled Cohort Equations to calculate 10-year risk of CVD events (see Note 1), a risk-based treatment decision is uncertain
The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of a patient’s illness.

b) Testing for hs-CRP **DOES NOT MEET COVERAGE CRITERIA** for all other indications, including but not limited to all of the following:
   i) Use as a screening test for the general population
   ii) For monitoring response to therapy

5) High-sensitivity Cardiac Troponin

Measurement of High-sensitivity cardiac troponin T (hs-cTnT) **DOES NOT MEET COVERAGE CRITERIA** for cardiovascular risk assessment and stratification in the outpatient setting.

6) Gene expression testing to predict coronary artery disease

Gene expression testing to predict coronary artery disease (CAD) **DOES NOT MEET COVERAGE CRITERIA** for all indications, including but not limited to prediction of the likelihood of CAD in stable, nondiabetic patients.

7) Homocysteine

Homocysteine testing for cardiovascular disease risk assessment screening, evaluation, and management **DOES NOT MEET COVERAGE CRITERIA**. Homocysteine testing for indications other than CVD is addressed in Avalon Policy AHS-M2141-Testing of Homocysteine Metabolism-Related Conditions and AHS-G2014-Vitamin B12 and Methylmalonic Acid Testing.

   (Rationale note - Avalon covers other alternative tests (e.g., lipid panel) which are widely used and equally valuable in CV risk assessment)

8) Novel Cardiovascular Biomarkers

Measurement of novel lipid and non–lipid biomarkers (eg., apolipoprotein AI, apolipoprotein E, B-type natriuretic peptide, cystatin C, fibrinogen, leptin, LDL subclass, HDL subclass) **DOES NOT MEET COVERAGE CRITERIA** as an adjunct to LDL cholesterol in the risk assessment of cardiovascular disease.

9) Cardiovascular Risk Panels

Cardiovascular risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels, see Policy Guidelines below), **DO NOT MEET COVERAGE CRITERIA**.

10) Serum Intermediate Density Lipoprotein

Measurement of serum intermediate density lipoproteins **DOES NOT MEET COVERAGE**
CRITERIA as an indicator of cardiovascular disease risk.

11) Lipoprotein-associated Phospholipase A2

Measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2) DOES NOT MEET COVERAGE CRITERIA as an indicator of risk of cardiovascular disease.

12) Long-chain Omega-3 Fatty Acid

Measurement of long-chain omega-3 fatty acids in red blood cell membranes, including but not limited to its use as a cardiac risk factor DOES NOT MEET COVERAGE CRITERIA.

13) The use of genotyping for 9p21 single nucleotide polymorphisms DOES NOT MEET COVERAGE CRITERIA for all indications, including identification of patients who may be at increased risk of cardiovascular disease or its manifestations. (e.g., MI, ischemic stroke, peripheral arterial disease, coronary artery calcification) or identification of patients who may be at increased risk for aneurysmal disease (abdominal aortic aneurysms, intracranial aneurysms, polyoidal choroidal vasculopathy).

14) KIF6 Genotyping DOES NOT MEET COVERAGE CRITERIA for predicting cardiovascular risk and/or the effectiveness of statin therapy.

15) All other tests for assessing CHD risk DO NOT MEET COVERAGE CRITERIA.

Note 1:
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk (Goff et al., 2014):
Risk factors include gender, age, race, smoking, hypertension, diabetes, total cholesterol, high and low density lipoprotein cholesterol. A race- and sex-specific PCE ASCVD Risk Estimator is available at:

The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol affirms that “the PCE is a powerful tool to predict population risk, but it has limitations when applied to individuals.” Hence a clinician-patient risk discussion can individualize risk status based on PCE, but with the inclusion of additional risk-enhancing factors. These additional factors may include:

- A family history of premature ASCVD (males, age <55 y; females, age <65 y)
- Primary hypercholesterolemia (LDL-C, 160–189 mg/dL [4.1–4.8 mmol/L]; non–HDL-C 190–219 mg/dL [4.9–5.6 mmol/L])
- Metabolic syndrome (increased waist circumference, elevated triglycerides [>150 mg/dL], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 in women mg/dL] are factors; tally of 3 makes the diagnosis)
- Chronic kidney disease (eGFR 15–59 mL/min/1.73 m2 with or without albuminuria; not treated with dialysis or kidney transplantation)
- Chronic inflammatory conditions such as psoriasis, RA, or HIV/AIDS
• History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that increase later ASCVD risk such as preeclampsia
• High-risk race/ethnicities (eg, South Asian ancestry)
• Lipid/biomarkers: Associated with increased ASCVD risk
• Persistently elevated, primary hypertriglyceridemia (≥175 mg/dL)
• Elevated high-sensitivity C-reactive protein (≥2.0 mg/L)
• Elevated Lp(a): A relative indication for its measurement is family history of premature ASCVD. An Lp(a) ≥50 mg/dL or ≥125 nmol/L constitutes a risk-enhancing factor especially at higher levels of Lp(a)
• Elevated apoB ≥130 mg/dL: A relative indication for its measurement would be triglyceride ≥200 mg/dL. A level ≥130 mg/dL corresponds to an LDL-C ≥160 mg/dL and constitutes a risk-enhancing factor
• ABI <0.9

Policy Guidelines:
A simple lipid panel is generally composed of the following lipid markers:
• Total cholesterol
• LDL cholesterol
• HDL cholesterol
• Triglycerides

Certain calculated ratios, such as the total/HDL cholesterol may also be reported as part of a simple lipid panel.

Other types of lipid testing, i.e., apolipoproteins, lipid particle number or particle size, lipoprotein (a), etc., are not considered to be components of a simple lipid profile.

IV. Table of Terminology

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>Arachidonic acid</td>
</tr>
<tr>
<td>AACE</td>
<td>American Association of Clinical Endocrinologists</td>
</tr>
<tr>
<td>AACVPR</td>
<td>American Association of Cardiovascular and Pulmonary Rehabilitation</td>
</tr>
<tr>
<td>AAPA</td>
<td>American Academy of Physician Assistants</td>
</tr>
<tr>
<td>ABC</td>
<td>Association of Black Cardiologists</td>
</tr>
<tr>
<td>ABI</td>
<td>Ankle-brachial index</td>
</tr>
<tr>
<td>ACC</td>
<td>American College of Cardiology</td>
</tr>
<tr>
<td>ACCF</td>
<td>American College of Cardiology Foundation</td>
</tr>
<tr>
<td>ACE</td>
<td>American College of Endocrinology</td>
</tr>
<tr>
<td>ACPM</td>
<td>American College of Preventive Medicine</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>ADA</td>
<td>American Diabetes Association</td>
</tr>
<tr>
<td>ADMA</td>
<td>Asymmetric dimethylarginine</td>
</tr>
<tr>
<td>AGS</td>
<td>American Geriatrics Society</td>
</tr>
<tr>
<td>AHA</td>
<td>American Heart Association</td>
</tr>
<tr>
<td>Anti-CCP</td>
<td>Anti-cyclic citrullinated peptide</td>
</tr>
<tr>
<td>APhA</td>
<td>American Pharmacists Association</td>
</tr>
<tr>
<td>Apo A-I</td>
<td>Apolipoprotein A-I</td>
</tr>
<tr>
<td>Apo B</td>
<td>Apolipoprotein B</td>
</tr>
<tr>
<td>Apo C-III</td>
<td>Apolipoprotein C-III</td>
</tr>
<tr>
<td>Apo E</td>
<td>Apolipoprotein E</td>
</tr>
<tr>
<td>APs</td>
<td>Antipsychotics</td>
</tr>
<tr>
<td>ART</td>
<td>Antiretroviral therapy</td>
</tr>
<tr>
<td>ASCP</td>
<td>American Society for Clinical Pathology</td>
</tr>
<tr>
<td>ASCVD</td>
<td>Atherosclerotic cardiovascular disease</td>
</tr>
<tr>
<td>ASH</td>
<td>American Society of Hypertension</td>
</tr>
<tr>
<td>ASPC</td>
<td>American Society for Preventive Cardiology</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BNP</td>
<td>Brain natriuretic peptide</td>
</tr>
<tr>
<td>CAC</td>
<td>Coronary artery calcium</td>
</tr>
<tr>
<td>CAC</td>
<td>Coronary artery calcification</td>
</tr>
<tr>
<td>CAD</td>
<td>Coronary artery disease</td>
</tr>
<tr>
<td>CC</td>
<td>Coverage criteria</td>
</tr>
<tr>
<td>C-CHANGE</td>
<td>Canadian Cardiovascular Harmonized National Guidelines Endeavour</td>
</tr>
<tr>
<td>CCS</td>
<td>Canadian Cardiovascular Society</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CHARGE</td>
<td>Cohorts for Heart and Aging Research in Genomic Epidemiology</td>
</tr>
<tr>
<td>CHD</td>
<td>Coronary heart disease</td>
</tr>
<tr>
<td>CIMT</td>
<td>Carotid intima media thickness</td>
</tr>
<tr>
<td>CK</td>
<td>Creatine kinase</td>
</tr>
<tr>
<td>CKD</td>
<td>Chronic kidney disease</td>
</tr>
<tr>
<td>CRP</td>
<td>C reactive protein</td>
</tr>
<tr>
<td>cTnl</td>
<td>Cardiac troponin I</td>
</tr>
<tr>
<td>cTnT</td>
<td>Cardiac troponin T</td>
</tr>
<tr>
<td>CVD</td>
<td>Cardiovascular disease</td>
</tr>
<tr>
<td>DHA</td>
<td>Docosahexaenoic acid</td>
</tr>
<tr>
<td>DM</td>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>DoD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>DPA</td>
<td>Docosapentaenoic acid</td>
</tr>
<tr>
<td>EACPR</td>
<td>European Association for Cardiovascular Prevention &amp; Rehabilitation</td>
</tr>
<tr>
<td>EAS</td>
<td>European Atherosclerosis Society</td>
</tr>
<tr>
<td>EASD</td>
<td>European Association for the Study of Diabetes</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>EEG</td>
<td>Electroencephalography</td>
</tr>
<tr>
<td>ELISA</td>
<td>Enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>EPA</td>
<td>Eicosapentaenoic acid</td>
</tr>
<tr>
<td>ES</td>
<td>Endocrine Society</td>
</tr>
<tr>
<td>ESC</td>
<td>European Society of Cardiology</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FH</td>
<td>Familial hypercholesterolemia</td>
</tr>
<tr>
<td>FHx</td>
<td>Family history</td>
</tr>
<tr>
<td>GDMT</td>
<td>Guideline-directed medical therapy</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular filtration rate</td>
</tr>
<tr>
<td>GGT</td>
<td>Gamma-glutamyltransferase</td>
</tr>
<tr>
<td>GRS</td>
<td>Genomic risk score</td>
</tr>
<tr>
<td>GWAS</td>
<td>Genome-wide association study</td>
</tr>
<tr>
<td>HDL</td>
<td>High-density lipoprotein</td>
</tr>
<tr>
<td>HDL-C</td>
<td>High-density lipoprotein cholesterol</td>
</tr>
<tr>
<td>HF</td>
<td>Heart failure</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HRs</td>
<td>Hazard ratios</td>
</tr>
<tr>
<td>hsCRP</td>
<td>High-sensitivity C Reactive Protein</td>
</tr>
<tr>
<td>hs-cTnI</td>
<td>High-sensitivity cardiac troponin i</td>
</tr>
<tr>
<td>hs-cTnT</td>
<td>High-sensitivity cardiac troponin t</td>
</tr>
<tr>
<td>IDEAL</td>
<td>Incremental Decrease in End Points Through Aggressive Lipid-Lowering</td>
</tr>
<tr>
<td>IDL</td>
<td>Intermediate density lipoproteins</td>
</tr>
<tr>
<td>KIF6</td>
<td>Kinesin family member 6</td>
</tr>
<tr>
<td>KIF6</td>
<td>Kinesin-like protein 6</td>
</tr>
<tr>
<td>LDL</td>
<td>Low-density lipoprotein</td>
</tr>
<tr>
<td>LDL-C</td>
<td>Low-density lipoprotein cholesterol</td>
</tr>
<tr>
<td>LDTs</td>
<td>Laboratory-Developed Tests</td>
</tr>
<tr>
<td>LMBP</td>
<td>Laboratory Medicine Best Practices</td>
</tr>
<tr>
<td>Lp(a)</td>
<td>Lipoprotein A</td>
</tr>
<tr>
<td>LPA</td>
<td>Apolipoprotein(a) locus</td>
</tr>
<tr>
<td>Lp-PLA2</td>
<td>Lipoprotein-associated Phospholipase A2</td>
</tr>
<tr>
<td>LSP</td>
<td>Lipids Standardization Program</td>
</tr>
<tr>
<td>MESA</td>
<td>Multi-Ethnic Study of Atherosclerosis</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Care Excellence</td>
</tr>
<tr>
<td>NLA</td>
<td>National Lipid Association</td>
</tr>
<tr>
<td>NMA</td>
<td>National Medical Association</td>
</tr>
<tr>
<td>Non-HDL-C</td>
<td>Non-high-density lipoprotein cholesterol</td>
</tr>
<tr>
<td>NT-proBNP</td>
<td>Amino-terminal pro-B-type natriuretic peptide</td>
</tr>
</tbody>
</table>
V. Scientific Background

Statistics show that cardiovascular disease (including coronary heart disease, stroke and hypertension) is America's leading health problem, and the leading cause of death. According to the 2020 update of the heart disease and stroke statistics report released by the American Heart Association:

- Approximately 121 million people in this country suffer from some form of cardiovascular disease (encompassing coronary heart disease, heart failure, hypertension, and stroke).

- The direct and indirect costs of cardiovascular disease and stroke are about $351.3 billion and increasing every year.

- An estimated 18 million U.S. adults have coronary heart disease, 116 million U.S. adults have high blood pressure, and 26 million have diabetes.

- Heart failure affects over 6 million U.S. adults.

- On average, someone in the U.S. suffers a stroke every 40 seconds.

- Women have a higher lifetime risk of stroke than men.

- Approximately 15 percent of U.S. adults smoke cigarettes “some days” or “every day”.

- An estimated 68 percent of U.S. adults are overweight or obese (Virani Salim et al., 2020).
Cardiovascular Risk Assessment

Traditionally, the most important indicators for cardiac risk are those of a person's health history. These include factors such as family history, age, weight, exercise, and cigarette smoking status (Wilson, 2020b).

Tests typically used to assess cardiovascular risk include:

1. Lipid profile or panel, which is the most important blood test for cardiac risk assessment
2. Biomarkers
3. Cardiovascular Risk Panels

Lipid Profile or Panel

A lipid profile or lipid panel is a panel of blood tests that serves as an initial broad medical screening tool for abnormalities in lipids, such as cholesterol and triglycerides. The results of this test can identify certain genetic diseases and can determine approximate risks for cardiovascular disease and other diseases. The lipid profile typically includes measurements of low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and total cholesterol. Using these values, a laboratory may also calculate the very low-density lipoprotein (VLDL) and total cholesterol/HDL cholesterol ratio (R. Rosenson, 2020d).

Biomarkers

Traditional risk algorithms may miss up to 20% of cardiovascular disease (CVD) events (MacNamara et al., 2015). Numerous biomarkers have been proposed as potential risk markers for CVD. These biomarkers include but are not limited to several apolipoproteins (A, B, AI, E, LDL, HDL), B-type natriuretic peptide, and C-reactive protein. These biomarkers have been proposed as an alternative or addition for risk stratification in CVD or as treatment targets for lipid-lowering therapy (R. Rosenson, 2020b, 2020c; Wilson, 2020a). However, even the most promising biomarkers have only demonstrated modest associations and predictive ability.

Apolipoprotein B (Apo B)

Apo B is a major protein in the construction and regulation of lipids. There are two forms of apo B, apo B-48 and apo B-100. Apo B-100 is the major protein found in LDL and VLDL. Each LDL particle has one molecule of Apo B-100 per particle. Therefore, the apo B concentration may represent the amount of LDL well (Rosenson, 2017; R. Rosenson, 2020b, 2020d). Increased levels of apo B have been associated with atherosclerosis development in several large-scale studies; however, apo B levels have yet to become routinely measured in clinical practice (Morita, 2016; Trompet et al., 2018).

Researchers have hypothesized that lowering apo B levels in young or middle-aged individuals will reduce the number of atherosclerosis cases later in life (Robinson et al., 2018). Further, atherosclerotic changes in retinal arteries have been associated with coronary artery disease (CAD) as well as apo B, TG, TC, and LDL-C levels (Tedeschi-Reiner et al., 2005). Lamprea-
Montealegre et al. (2020) have analyzed data from 9270 participants with chronic kidney disease to determine if triglyceride-rich lipoproteins contribute to a greater CVD risk in this population; it was determined that increased apo B along with other triglyceride and cholesterol-related concentrations were associated with an increased risk for atherosclerotic CVD risk in chronic kidney disease patients. A second study (n=8570) has researched the relationship between apo B levels relative to LDL-C and non-LDL-C, as well as how these levels affect subclinical atherosclerotic cardiovascular disease (ASCVD) (Cao et al., 2019). Results showed that higher apo B levels were associated with an increase in coronary artery calcium (CAC) levels among adults older than 45 years who were not taking statins, “but provided only modest additional predictive value of apo B for CAC prevalence, incidence, or progression beyond LDL-C or non-HDL-C (Cao et al., 2019).” An equation to predict major cardiovascular events based on apo B levels has even been developed, and when studied, this equation showed major cardiovascular event “risk prediction comparable to directly-measured apo B in high risk patients with previous coronary heart disease (Hwang et al., 2017).”

The 2019 European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) published guidelines for the management of dyslipidaemias. These guidelines stated that “ApoB analysis is recommended for risk assessment, particularly in people with high TG [triglycerides], Diabetes mellitus (DM), obesity or metabolic syndrome, or very low LDL-C (Mach et al., 2019).” The ESC and EAS justify these recommendations by stating that the measurement of LDL-C levels in patients with dyslipidaemia may be inaccurate due to high DM or TG levels. “Because apo B provides an accurate estimate of the total concentration of atherogenic particles under all circumstances, it is the preferred measurement to further refine the estimate of ASCVD risk that is modifiable by lipid-lowering therapy (Mach et al., 2019).”

**Apolipoprotein A-I (Apo-A-I)**

Apo A-I is a lipid-binding protein which comprises HDL molecules. HDL contains two associated apolipoproteins, A-I and A-II, and together they are the primary components of the HDL molecules. Due to Apo A-I’s role as a primary structural protein for HDL, it significantly factors into the density ranges of HDL, which ultimately contribute to their overall measurement (R. Rosenson, 2020b).

Direct measurement of apo A-I has been proposed as more accurate than the traditional use of HDL level. Low levels of apo A–I may be associated with an increased risk for CVD. Testing for apo A–I is often performed with apolipoprotein B and reported as a ratio (apo B: apo A-I), thus providing a measure of atherogenic to antiatherogenic lipoprotein particles (Sandhu et al., 2016).

**Apolipoprotein E (Apo E)**

Apo E is the primary apolipoprotein found in VLDLs and chylomicrons. Apo E is essential in the metabolism of cholesterol and triglycerides and helps to clear chylomicrons and VLDL. Apo E polymorphisms have functional effects on lipoprotein metabolism. Some Apo E genotypes are more atherogenic than others, and their measurement could provide additional information of risk of coronary artery disease (Rosenson, 2017; R. Rosenson, 2020b).
**B-type or Brain Natriuretic Peptide (BNP)**

BNP is a hormone released by the ventricles of the heart when pressure to the cardiac muscles increases or there is volume overload. BNP is now an established biochemical marker for heart failure, as the level of BNP in plasma increases proportionally based on disease severity (Kuwahara et al., 2018). Further, BNP has been accepted as an “independent surrogate marker of rehospitalization and death” for heart disease (Li & Wang, 2005), and exhibits both diagnostic and prognostic capabilities (Tomcsányi et al., 2018).

While BNP has shown great promise for diagnostic congestive heart failure purposes, a BNP guided heart failure treatment strategy seems to be controversial; some report that this type of treatment has led to greater health-related costs and does not increase patient outcomes (Mark et al., 2018). Still, many drugs, such as beta blockers, amiodarone, spironolactone, and angiotensin converting enzyme inhibitors, have been beneficial in reduction of circulating BNP during the management of chronic heart failure (Li & Wang, 2005). A major limitation of BNP is that a wide range of values are observed in patients with and without heart failure; for example, obese individuals tend to have lower levels of this hormone than healthy individuals (Colucci, 2019).

Januzzi et al. (2019) used data from the GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) trial to develop a greater understanding of the prognostic capabilities of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) following heart failure. A total of 638 individuals participated in the study. The authors concluded that “Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to ≤1,000 pg/ml during GDMT [guideline-directed medical therapy] had better outcomes” (Januzzi et al., 2019). These results highlight the potential for NT-proBNP to be used as a prognostic tool following heart failure.

**High Density Lipoprotein (HDL)**

Apart from apolipoprotein content (AI and AII), HDL can be classified by size (small and large), by density (HDL2, HDL3), and by electrical charge (pre-beta, alpha and pre-alpha). There has been substantial interest in evaluating whether HDL subclass testing can be used to provide additional information on cardiovascular risk compared to HDL alone. HDL levels have been noted to be inversely related to CVD risk and possibly even protective against CVD. However, there are still many questions about the relationship between HDL and CVD risk, such as whether HDL levels are causative of lower CVD risk (R. Rosenson, 2020a, 2020b).

**Low Density Lipoprotein (LDL)**

LDL proteins are a significant risk factor in predicting atherosclerosis. The mechanism of how LDL subclass particles impact risk of CVD has not been determined although many mechanisms have been proposed. Even though LDL cholesterol levels may be normal, an elevation of small, dense LDL particles may be associated with CVD. One theory is that the small LDL particles can be more easily deposited into the intima, lead to atherosclerosis, and eventually CVD. Another is that LDL particles may upregulate the angiotensin II receptor, thereby promoting atherosclerosis (Rosenson, 2017; R. Rosenson, 2020b).
Lipoprotein(a)

Lipoprotein(a) (Lp(a)) is a low-density lipoprotein and has been determined to have atherogenic potential. Lp(a) has been proposed as an independent risk factor for coronary artery disease (CAD). Although research has shown it accumulates in atherosclerotic lesions, the actual process remains unclear. Serum levels of Lp(a) are highly determined by genetic polymorphisms, and the 90th percentile of Lp(a) levels was estimated at about 39 mg/dL. The overall degree of risk associated with Lp(a) levels appears to be modest, and the degree of risk may be mediated by other factors such as LDL levels and/or hormonal status. The standard method for measuring Lp(a) is density gradient ultracentrifugation. Although enzyme-linked immunosorbent assay (ELISA) techniques are available; they unable to distinguish between apo(a) isoforms, leading to inaccurate results (Rosenson, 2018). Lp(a) may have prognostic value in certain situations, such as in women with hypercholesterolemia (Grundy et al., 2019).

A study focusing on the possible role of Lp(a) in CVD was performed by Willeit et al. (2018); 26069 subjects were analyzed, and the authors found a linear relationship between elevated Lp(a) levels and CVD risk at a baseline of ≥30 mg/dL and an on-statin level of ≥50 mg/dL. The baseline hazard ratios were 1.13 and 1.36 for 30-50 mg/dL and >50 mg/dL respectively, and the hazard ratios for patients on statins were 1.08 and 1.42 respectively (Willeit et al., 2018).

Mehta et al. (2020) investigated “independent and joint associations of Lp(a) and FHx [family history of coronary heart disease] with atherosclerotic cardiovascular disease (ASCVD) and CHD [coronary heart disease] among asymptomatic subjects.” A total of 12149 patients were included and observed over 21 years. The median age of this cohort was 54 years, and 44% of these patients had FHx. A total of 3114 ASCVD events were observed. Both FHx and elevated Lp(a) were independently associated with ASCVD, with a hazard ratio of 1.17 for FHx and a hazard ratio of 1.25 for elevated Lp(a). Patients with both FHx and elevated Lp(a) were found to have a hazard ratio of 1.43. Similar findings were found for CHD. The authors also noted that ASCVD and CHD risk reclassification and discrimination indices had improved accuracy with both FHx and Lp(a) included. The authors concluded that “elevated plasma Lp(a) and FHx have independent and additive joint associations with cardiovascular risk and may be useful concurrently for guiding primary prevention therapy decisions” (Mehta et al., 2020).

Cystatin C

Cystatin C is a protease inhibitor protein that plays a role in inflammation and obesity. Serum testing has been proposed to diagnose impaired kidney function, which in turn may be a risk factor for coronary heart disease (Rule, 2020). There is no published literature proving the effectiveness of Cystatin C as a biomarker for predicting cardiovascular risk and other confounding factors such as inflammation levels still need to be parsed out from Cystatin C. Overall, Cystatin C is not routinely used as a CVD biomarker (Sarnak, 2019).

Fibrinogen

Fibrinogen is a circulating glycoprotein that plays an important role in platelet aggregation and blood viscosity. Fibrinogen has been suggested as a possible indicator of inflammation that accompanies atherosclerosis. The independent predictive power, impact on management
strategies, and clinical utility of fibrinogen measurement have shown conflicting results. One study of 150000 subjects demonstrated a log-linear relationship of fibrinogen and cardiovascular events, but another study of 90000 subjects did not find a relationship; therefore further research is required (Wilson, 2017, 2020b). A recent study has reported that higher fibrinogen levels increased the risk of a stroke in large arteries or small vessels but decreased the risk of cardioembolic stroke (Maners et al., 2019).

Pieters et al. investigated the contribution of fibrinogen, as well as other biomarkers, on cardiovascular disease (CVD) mortality. A total of 4487 patients were evaluated over a period of 14 years. The authors noted that 551 patients had CVD at baseline and over the time period investigated, 321 CVD deaths occurred. Fibrinogen was found to associate (“cluster”) with C-Reactive protein only and was associated with both baseline CVD and CVD mortality at follow-up. Both fibrinogen and gamma-glutamyl transferase were found to be mediators between CVD status and all-cause mortality, as well as between CVD status and CVD mortality (Pieters et al., 2020).

**Leptin**

Leptin is a protein secreted by fat cells and plays a role in fat metabolism. As leptin increases with obesity, it is thought to be associated with CVD. Leptin may play a role in regulating blood pressure, insulin sensitivity, inflammatory vascular responses, and more. However, a meta-analysis covering 13 studies, 4257 CVD patients, and 26710 controls indicated no significant relationship between leptin and CVD or stroke once other cardiovascular risk factors were controlled. The authors recommend further research to evaluate the effectiveness of leptin as a predictor of CVD (Wilson, 2017, 2020b; Yang et al., 2017). A recent study found that, in a Chinese cohort, serum leptin levels were identified as a marker for patients with first-ever acute ischemic stroke and were also associated with stroke size and severity (Liu et al., 2019).

**Drug Therapies Requiring Lipid Monitoring**

**Lipid-lowering Therapy with Statins**

Statins, such as ezetimibe, are a type of drug often prescribed to lower lipid levels or cholesterol. Pignone (2020) has reported that statins may reduce CVD risk by 20 to 30%, regardless of initial LDL-C levels. Statins are also beneficial for the treatment of arterial stiffness, independent of their hypolipidemic effect; treatment with a high dosage of statins will decrease LDL-C levels and improve arterial stiffness levels (Reklou et al., 2020). Kongpakwattana et al. (2019) report that the use of statin therapy in combination with non-stain lipid-modifying agents is more beneficial to reduce CVD risk than using only one treatment method.

A meta-analysis of statin trials completed by Boekholdt et al. (2014) analyzed data from 38,153 patients. During the follow-up of only 5,387 patients, it was found that 6,286 major cardiac events occurred. Great variability was recorded in LDL-C, apo B and non-HDL-C levels based on fixed statin levels over a one-year period. “Among trial participants treated with high-dose statin therapy, >40% did not reach an LDL-C target <70 mg/dl,” suggesting that high-dose statin therapy effectiveness may depend on the individual (Boekholdt et al., 2014).
Antipsychotics

Several atypical antipsychotic medications, such as risperidone, sertindole and olanzapine, have been FDA approved for the treatment of psychiatric disorders, including bipolar disorder, depression, and schizophrenia; unfortunately, these medications may lead to a plethora of side effects, including dyslipidemia, hypertension, increased CVD risk, obesity, sudden cardiac death, and insulin resistance (Beauchemin et al., 2019; Polcwiartek et al., 2016). Specifically, antipsychotic-induced corrected QT prolongation may increase the risk of Torsades de Pointes (a form of polymorphic ventricular tachycardia), leading to sudden cardiac death (Polcwiartek et al., 2016). While newer antipsychotics have been improved to lessen the pro-arrhythmic impact of their predecessors, they may contribute to cardiac death in a new way: by worsening the metabolic profile (Howell et al., 2019). It is recommended that any individuals in need of antipsychotics seriously consider the risks of these medications before accepting this type of treatment.

A ten-year study compared the CVD risk of patients with schizophrenia taking antipsychotics with healthy controls. The overall CVD risk was 5.16% in patients with schizophrenia, and 3.02% in the healthy control group; further, risk scores were significantly higher and HDL levels were significantly lower in patients taking multiple antipsychotics (Kilicaslan et al., 2019). A recent meta-analysis by Rotella et al. (2020) aimed to identify the long-term metabolic and cardiovascular effects of antipsychotic drugs. A total of 3013 studies were screened, and 92 were used for data analysis. The researchers have found a significantly higher risk of CVD death for sertindole users compared to risperidone users and state that “Long-term cardiovascular effects of APs [antipsychotics] deserve to be studied more extensively (Rotella et al., 2020).”

Accutane

Accutane, also known as isotretinoin, is a synthetic vitamin A derivative and oral medication often prescribed for the treatment of severe acne; it was approved by the FDA in 1982 to treat resistant, nodular acne that has not responded to conventional therapeutic measures such as systemic antibiotics (Pile & Sadiq, 2019). Unfortunately, isotretinoin therapy may cause various cardiac events, including congenital heart disease, atrial tachycardia, and cardiac remodeling (Guler et al., 2015). Akcay and Yuksel (2019) have reported that isotretinoin use may have been related to the development of Kounis syndrome (acute coronary syndrome due to a reduction of blood flow to the heart) in one patient. Alan et al. (2016) reported that isotretinoin use may have triggered premature ventricular contractions in a 33-year old woman. Karadag et al. (2012) completed a study comprised of 70 patients who were being treated with 0.5-1.0 mg/kg per day of isotretinoin; in each patient, heart rate, blood pressure, EEG, biochemical and hematologic parameters were all measured. “We found that isotretinoin did not affect P- and QT-wave measurement (Karadag et al., 2012).”

Isotretinoin may also affect serum lipid levels. Zane et al. (2006) studied 13772 patients with acne currently receiving oral isotretinoin therapy. Results showed that 31% of isotretinoin users had high cholesterol levels, 11% had high liver transaminase levels, and 44% had high triglyceride levels (Zane et al., 2006). In a more recent study, Lee et al. (2016) completed a systematic review and meta-analysis from 1960-2013 which studied the effects of oral isotretinoin use. Data was only admitted if 40 mg/day of isotretinoin was used for at least four
weeks. The authors stated that “This meta-analysis showed that (1) isotretinoin is associated with a statistically significant change in the mean value of several laboratory tests (white blood cell count and hepatic and lipid panels), yet (2) the mean changes across a patient group did not meet a priori criteria for high-risk and (3) the proportion of patients with laboratory abnormalities was low (Lee et al., 2016; Zane et al., 2006).” The authors concluded by stating that these results do not support monthly laboratory testing for patients taking standard isotretinoin doses for acne purposes.

Other Cardiovascular Markers

C Reactive Protein (CRP)

Data from numerous studies have shown an association between elevated serum or plasma concentrations of CRP and atherosclerotic vascular disease, risk of recurrent cardiovascular events, and the incidence of initial cardiovascular events among individuals not known to have atherosclerosis (Crea, 2020).

CRP can be measured using either traditional assays or high sensitivity CRP (hs-CRP) assays. Traditional assays have limited use when screening for cardiovascular disease due to their limit of detection (3-5 mg/L). On the other hand, hs-CRP assays can detect concentrations of CRP down to 0.3 mg/L and below. These hs-CRP assays are used to assess cardiovascular risk because they can detect and quantify CRP within the range normally seen in asymptomatic patients (<3 mg/L). Elevated CRP levels, either alone or in combination with other cardiovascular risk factors, have been associated with a higher risk of future cardiovascular events. Studies evaluating CRP in asymptomatic populations have shown that the baseline level of CRP predicts the long-term risk of a first myocardial infarction (MI), ischemic stroke, hypertension, peripheral vascular disease, sudden cardiac death, and all-cause mortality (Crea, 2018, 2020).

Homocysteine

Homocysteine is an amino acid that is produced by the body. Elevated levels of homocysteine may result in damage to the walls of the artery, increase the potential for thrombosis and lead to advanced atherosclerosis. Hence, elevated homocysteine levels have been demonstrated to increase the risk of CVD. However, the testing of homocysteine levels is not consistently recommended because, based on current research, the lowering of plasma homocysteine levels does not necessarily lower the risk of CVD. Further research is required to support the clinical utility of lowering homocysteine levels (R. S. Rosenson, Smith, C. Christopher, Bauer, Kenneth A., 2020).

Intermediate Density Lipoproteins (IDL)

Intermediate Density Lipoproteins (remnant cholesterol or lipoproteins) are the cholesterol content of triglyceride-rich lipoproteins, which is composed of VLDL and IDL in the fasting state, and is a combination of VLDL, IDL, and chylomicron remnants in the non-fasting state. It can be estimated by triglyceride (TG) levels in the absence of advanced lipoprotein testing. Elevated non-fasting plasma triglyceride is associated with increased risk for CVD (Varbo et al., 2013). Triglycerides are unlikely to directly cause CVD, thus VLDL and IDL are more
commonly identified as the source of this increased risk for CVD (Jepsen et al., 2016). VLDL and IDL have been shown to be proatherogenic with both proinflammatory and prothrombotic effects (Joshi et al., 2016).

Genetic case studies have shown that elevated levels of remnant cholesterol are causally associated with both low-grade inflammation and CVD. Elevated levels of LDL cholesterol are associated with CVD, but not with low-grade inflammation. This indicates that elevated LDL cholesterol levels cause atherosclerosis without inflammation, whereas elevated remnant cholesterol levels lead to both atherosclerosis and inflammation (Varbo et al., 2014; Varbo et al., 2013).

Another measure which includes IDL is Non-HDL-C, which is derived from the simple calculation of total cholesterol minus HDL-C. The Emerging Risk Factors Collaboration concluded that apoB and non-HDL-C predicted risk similar to directly measured LDL-C and that fasting did not affect the hazard ratios (HRs) (Di Angelantonio et al., 2009).

**Lipoprotein-associated Phospholipase A2 (Lp-PLA2)**

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory enzyme expressed in atherosclerotic plaques. It has been proposed that Lp–PLA2 testing may aid in detecting CVD risk due to its association with other biomarkers, such as LDL. The rationale for Lp-PLA2 as a key inflammatory biomarker is attractive because this enzyme is produced in atherosclerotic plaques with elevated expression found in CVD patients (Rosenson & Stafforini, 2012).

Numerous studies evaluate Lp-PLA2 as a predictor of cardiovascular risk (Garg et al., 2015; LPSC, 2010; Sudhir, 2006). These studies demonstrate that Lp-PLA2 is an independent predictor of CVD. Preliminary clinical trials of Lp-PLA2 inhibitors showed some improvements in physiologic measures, such as reduction in hs-CRP (Sudhir, 2006). However, further clinical trials of Lp-PLA2 inhibitors failed to demonstrate significant improvements in patient outcomes (Mohler et al., 2008). Although Lp-PLA2 does not appear to have any predictive power with apparently healthy individuals, it may have utility for symptomatic patients. The link between the enzyme and LDL is found in the enzyme’s plasma activity, which tends to vanish with treatment (Rosenson & Stafforini, 2012). De Stefano et al. (2019) stated that Lp-PLA2 may be considered as a new vascular specific biomarker to predict CVD in a population of patients with metabolic diseases.

**Long-Chain Omega-3 Fatty Acids**

Omega-3 fatty acids, a specific group of polyunsaturated fatty acids containing a double bond three carbons from the methyl terminus, are main building blocks of many fats and oils. Long-chain omega 3 fatty acids (≥C20, LC) include eicosapentaenoic acid (EPA, 20:5ω3), docosapentaenoic acid (DPA, 22:5ω3) and docosahexaenoic acid (DHA, 22:6ω3) and are thought to be beneficial in the prevention of coronary heart disease (CHD) (Mozaffarian, 2019). Circulating blood levels of EPA and DHA are inversely and significantly associated with reduced CHD event risk (de Oliveira Otto et al., 2013). Blood levels of omega-3 fatty acids may be more
related to CVD benefit than the daily dose of fish oil supplements (Superko et al., 2014). The blood EPA/arachidonic acid (AA) ratio may be a clinically relevant measurement as AA has atherogenic and thrombogenic metabolites. Although this ratio has substantial individual variability, an EPA/AA ratio >0.75 has been associated with a significantly lower number of major coronary events in a Japanese population (Itakura et al., 2011). Determination of blood omega-3 levels may help guide the appropriate use of dietary fish or omega-3 supplements in a personalized heart disease prevention strategy.

The relationship of fish and dietary omega-3 fatty acids and cardiovascular disease (CVD) has been investigated in numerous studies and comprehensive reviews and recommendations exist, but guidance on blood concentrations is missing. Some prospective fish oil treatment investigations report a significant reduction in CVD events, but others do not (Bosch et al., 2012; Itakura et al., 2011). A meta-analysis did not find a statistically significant relationship between omega-3 consumption and CVD mortality (Rizos et al., 2012). A science advisory from the AHA stated that for individuals with prevalent CHD such as a recent MI event, treatment with omega-3 PUFA supplements is reasonable; further, for patients with prevalent heart failure without preserved left ventricular function, fish oil treatment is recommended, while treatment is not recommended for patients with diabetes mellitus, prediabetes or as a method for stroke prevention (Siscovick et al., 2017).

**Troponins (I, T)**

Troponins are specific biomarkers for cardiac injury and are often used to diagnose myocardial infarctions. These proteins control the calcium-mediated interaction of actin and myosin in the muscle, and the cardiac versions of these proteins are unique to the heart. There are two primary categories of tests for troponins; “sensitive or contemporary” and “high-sensitive.” The high-sensitive version is preferred due to its superior accuracy (Gibson, 2020; Jaffe, 2020, 2019).

Elevated levels of troponins are proposed to predict CVD risk. Ford et al. (2016) performed a study evaluating troponin levels in 3318 men in relation to CVD risk. A hazard ratio of 2.3 for the highest quartile of troponin (≥5.2 ng/L) compared to the lowest quartile (≤3.1 ng/L) was found. The authors also found a 5-fold reduction in coronary events when troponin levels decreased by a quarter (Ford et al., 2016).

Tang et al. evaluated the ability of high-sensitivity cardiac troponin I (hs-cTnI) to assess cardiovascular risk and mortality. A total of 5876 patients ages 66-90 years were included. A total of 1053 deaths (321 CVD-related) occurred, within a median follow-up of 6.3 years. Patients with an elevated hs-cTnI and without history of CVD had a similar mortality risk to patients with a CVD history but without an elevated hs-cTnI. However, after adjustment, elevated hs-cTnI was found to be associated with mortality risk, by a hazard ratio of 2.38 over low hs-cTnI and no CVD. Elevated hs-cTnI was found to be independently associated with incident CVD by a hazard ratio of 3.41, ASCVD (HR = 2.02) and heart failure (HR = 6.16). The authors concluded that “Hs-cTnI improves mortality and CVD risk stratification in older adults beyond traditional risk factors and improved model discrimination more than hs-cTnT for certain outcomes” (Tang et al., 2020)

Suthahar et al. “evaluate[d] associations of high-sensitivity cardiac troponin-T (cTnT) with
cardiovascular disease (CVD), heart failure (HF), and mortality in community-dwelling women and men”. A total of 8226 adults were included in the study. The authors detected cTnT levels in 1102 women and 2396 men. The authors found these baseline levels to be associated with a greater risk of developing CVD in women compared to men (women hazard ratio = 1.48, men hazard ratio = 1.20). Similar sex-related differences were found for heart failure and mortality. Women at 6 ng/L were also found to have significantly increased risk for CVD, HF, and mortality whereas men were only found to have significantly increased risk for CVD at the same level of cTnT (Suthahar et al., 2020).

**Genetic Markers**

According to the AHA in 2013, genomics serves several roles in cardiovascular health and disease, including disease prediction, discovery of genetic loci influencing CVD, functional evaluation of these genetic loci to understand mechanisms, and identification of therapeutic targets (Ganesh et al., 2013). The AHA notes that several clinically useful diagnostic tests have been discovered for single-gene CVDs. However, it is laborious to develop genetic testing for complex CVD because individual common variants have a smaller impact on risk. Furthermore, the influence of factors, such as environmental variables, phenotypic heterogeneity, and pathogenic complexity, makes understanding the genomics behind complex CVDs more difficult. Characterization of the clinical phenotype requires consideration of the clinical details of the diseases and traits under study (Ganesh et al., 2013). Many genetic loci and polymorphisms have been proposed to influence cardiovascular risk. Palotie et al. (2016) identified 49310 single nucleotide polymorphisms (SNPs), created a genomic risk score (GRS) based on those SNPs, and evaluated the GRS with five population cohorts totaling over 15000 samples. The GRS was found to result in a hazard ratio of 1.74 for the three Finnish population cohorts (n = 12676) and a hazard ratio of 1.28 for the two Framingham cohorts (n = 3406). The GRS was also found to capture different trajectories of absolute risk, with men in the top 20% attaining 10% cumulative CHD risk 12–18 y earlier than those in the bottom 20% (Palotie et al., 2016).

Gene expression changes, particularly in peripheral blood cells, may provide some information on CVD risk. Gene expression is thought to reflect the pathological state of the current cell, tissue, or organ system, therefore providing molecular insight on the status of cardiac tissue before clinical symptoms start to appear (Elashoff et al., 2011). Genetic variation may lead to vastly differing concentrations of many genetic products. For example, Zhernakova et al. (2018) evaluated the plasma concentrations of 92 cardiovascular disease-related proteins, of which 73 had a genetic association. Cis- and trans- isoforms of the protein quantitative trait loci produced genetic variation, and genetic variation combined with microbial variation produced an average of 17.5% variation of inter-individual variation in plasma proteins (Zhernakova et al., 2018).

Corus CAD by CardioDX is a test that integrates gene expression levels as well as other factors such as age to provide a risk score for coronary artery disease (CAD) (CardioDX, 2019). The risk score is reported from 1-40. A total of 23 genes are evaluated, including genes associated with neutrophil, natural killer cell, and T cell activation (Rosenberg et al., 2010). The test was validated by two separate studies (CardioDX, 2019). However, CardioDX shut down in January of 2019.

A total of 1343 nondiabetic patients from the PREDICT trial were sequentially allocated to
independent development (N= 694) and validation (N= 649) sets. At a score threshold of 14.75, corresponding to a disease likelihood of 20% from the validation set data, the sensitivity was 85% with a specificity of 43%, corresponding to negative and positive predictive values of 83% and 46%, respectively, with 33% of patients having scores below this value (Rosenberg et al., 2010).

Another study by Thomas et al. (2013) evaluated Corus CAD’s genomic risk score in patients referred for myocardial perfusion imaging. Blood samples from 431 patients were evaluated. The area under the receiving operating curve was found to be 0.79. The sensitivity, specificity, and negative predictive values were identified at 89%, 52%, and 96%, respectively, with a prespecified threshold of ≤15; approximately 46% of patients were identified below this score. The authors concluded that this genomic risk score outperformed clinical factors and myocardial perfusion imaging (Thomas et al., 2013).

9p21 SNP

Genetic determinants of the development CHD have been investigated in multiple studies with 46 SNPs across the genome significantly associated with an increased risk of CHD (Deloukas et al., 2013). The strongest association with CHD risk were linked to SNPs around locus 9p21 (Palomaki et al., 2010; Patel et al., 2014; Paynter et al., 2009; Samani et al., 2007; Wilson, 2017, 2020b). However, despite clear association between variants and incident CHD, locus 9p21 SNPs have not been definitively shown to significantly improve CHD risk prediction compared with traditional risk factors (Dutta et al., 2011; Palomaki et al., 2010; Paynter et al., 2009; Virani et al., 2012). Trenkwalder et al. (2019) identified an association between the LPA locus and an increased risk of aortic valve stenosis, particularly in patients without CAD; however, 9p21 was not associated with aortic valve stenosis. The pathophysiologic impact of these genetic variants likely varies depending on other environmental factors or comorbid conditions (Wilson, 2017, 2020b). Some proprietary labs such as Celera Corporation (now owned by Quest Diagnostics) and Decode Genetics offer tests revolving around testing of this gene mutation (Quest, 2019).

Palomaki et al. (2010) performed a targeted systematic review of published literature to evaluate the clinical utility of 9p21 single nucleotide polymorphism testing. Forty-seven distinct data sets from 22 articles were analyzed, including 35872 cases and 95837 controls. The authors found a statistically significant association between 9p21 SNPs and heart disease that varied by age at disease onset, but the magnitude of the association was small. These risk alleles were found to associate more strongly with cardiovascular events in younger persons than cardiovascular events overall. However, the authors noted that the clinical utility of 9p21-related biomarkers cannot be assumed due to numerous complicating factors such as patient adherence (Palomaki et al., 2010).

Gransbo et al. (2013) evaluated if testing for 9p21 SNP adds useful information to CVD prediction beyond assessment of traditional risk factors. The common SNP variant rs4977574, on chromosome 9p21, was genotyped in 24777 subjects who were free from CVD prior to the baseline examination. The genotyping of the 9p21 gene was not found to significantly improve predictive accuracy of CVD although 9p21 significantly predicted CVD in the whole population in additive models. The authors evaluated the attributable risk conferred by 9p21 to be 13%. The investigators concluded that a variation of chromosome 9p21 alone “does not add clinically meaningful information in terms of CVD prediction beyond traditional risk factors at any age”
Dehghan et al. (2016) evaluated the Genome-Wide association study (GWAS) for incident MI and CHD in prospective cohort studies, which analyzed a total of 64297 individuals, including 3898 MI cases and 5465 CHD cases. A modest association between the 9p21 locus SNP (rs1333049) and MI and marginal association with CHD was found. Among an inception cohort of those who experienced MI during follow-up, this risk allele was associated with a decreased risk of subsequent mortality. The authors concluded that the role of 9p21 locus may be complex and that the protective effect of the risk alleles at 9p21 is unclear; however, the authors note that several other studies have found that the 9p21 locus is increasing the CHD risk for the first event only and not for subsequent events. Overall, the authors suggest further investigation of genetic causes of complex disorders due to their unusual findings of the 9p21 gene (Dehghan et al., 2016).

Kessler et al. (2016) have reviewed the impact of GWAS on the pathophysiology and therapy of CVD. The researchers have found a correlation between the number of individuals participating in the study and the number of genome-wide significant variants detected by the GWAS. Progress in genotyping techniques has led to denser genotyping, resulting in increased number of loci with genome-wide significant association for CAD. Over 50 genetic variants associated with cardiovascular risk have been found. Almost all risk variants identified by GWAS were found in European individuals with the average European carrying several risk alleles associated with CHD. Most of these risk alleles were found in non-coding parts of genome, suggesting that these variants affect gene regulation rather than protein structure. For example, the 9p21 locus encodes different isoforms of antisense non-coding RNA in the INK4 locus (ANRIL) which is involved in the preferred synthesis of non-circular/circular forms of the long non-coding RNA, affecting expression of multiple genes (Kessler et al., 2016). The authors, however, state that variants identified represent no more than 10% of the heritable risk. Although an important progress was made with GWAS, further understanding of inheritance patterns is needed. The results available so far provided valuable insights into pathophysiology of CAD and MI, but they are only a starting point for individualized treatment strategies (Kessler et al., 2016).

In summary, no studies were found that outlined changes to preventive and monitoring strategies, patient management, or improvement in clinical outcomes due to genotyping for 9p21 SNPs. There is a lack of published evidence regarding the clinical utility of genetic testing. The contribution of 9p21 genotyping to overall cardiovascular risk assessment, above that of traditional risk factors, is not likely to be clinically important.

**Kinesin family member 6 (KIF6)**

Kinesin family member 6 (KIF6) is a protein encoded by the KIF6 gene. This protein is involved in transport along microtubules, and the primary mutation of Trp719Arg affects its ability to bind its cargo. KIF6 has been studied as a marker for coronary artery disease and effectiveness of statin therapy. Initial studies of two trials with statins found an association between the KIF6 p.Trp719Arg (rs20455, c.2155T>C) polymorphism and clinical outcomes with statin therapy, showing carriers of the 719Arg allele having greater reduction in clinical events compared with noncarriers (Iakoubova et al., 2008). However, subsequent studies dispute the reported associations.
Hopewell et al. (2011) studied the effects of the KIF6 Trp719Arg polymorphism (rs20455) on vascular risk and response to statin therapy in 18348 participants from the Heart Protection Study. Participants received 40 mg simvastatin daily for 4 to 6 weeks before being randomly allocated 40 mg simvastatin daily or placebo for 5 years. The KIF6 genotype was not significantly associated, among placebo-allocated participants, with the risks of incident major vascular events, major coronary events, revascularizations, or strokes. The investigators concluded that statin therapy significantly reduces the incidence of coronary and other major vascular events to a similar extent, irrespective of KIF6 genotype. The authors further stated that use of KIF6 genotyping to guide statin therapy is not warranted (Hopewell et al., 2011).

Ridker et al. (2011) evaluated the effect of polymorphism at rs20455 encoding the KIF6 719Arg allele on outcomes of 8781 Caucasian trial participants in the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study. Rosuvastatin was equally effective at reducing cardiovascular event rates among carriers and noncarriers of the KIF6 719Arg allele, and carriers of the 719Arg allele were not found to have more vascular events or a significant difference in hsCRP or lipid levels. The authors concluded that for rosvastatin there appears to be no clinical utility to screening for the KIF6 genotype as a method to determine vascular risk or to predict statin efficacy (Ridker et al., 2011).

Arsenault et al. (2012) evaluated if carriers of the KIF6 719Arg variant benefit more from statin therapy, in terms of CVD risk reduction, than noncarriers through two large prospective, randomized, double-blinded, controlled trials. A total of 10001 patients with stable CHD and LDL-C levels <130 mg/dL (3.4 mmol/L) of the Treating to New Targets (TNT) study were randomly assigned to receive either 10- or 80-mg of atorvastatin per day and followed up for a median of 4.9 years. 8888 patients with a history of myocardial infarction from the Incremental Decrease in End Points Through Aggressive Lipid-Lowering (IDEAL) study were randomly assigned to receive 20–40 mg of simvastatin or 80 mg of atorvastatin and followed up for a median of 4.8 years. The investigators concluded that carriers of the KIF6 719Arg allele were not at increased cardiovascular risk and did not obtain consistent cardiovascular benefit from high-dose statin therapy compared with noncarriers (Arsenault et al., 2012).

Charland et al. (2014) investigated the impact of providing KIF6 test results and risk information directly to 647 tested patients on 6-month statin adherence and persistence compared with concurrent non-tested matched controls. The investigators observed that significantly more tested patients were adherent and persisted on therapy compared to the control group, with tested patients rating out at a 63.4% adherence (defined as ingesting medication on 80% of days), compared to 45% for the control group over 6 months (Charland et al., 2014). The test group also persisted on therapy more often than the control group (69.1% for the testing group, 53.3% for the control). The investigators concluded that the study provided the first evidence that pharmacogenetic testing may modify patient adherence (Charland et al., 2014).

Ruiz-Ramos et al. (2015) performed a systematic review and meta-analysis of previously published association studies between Trp719Arg polymorphism of KIF6 and the development of CHD. This electronic search included papers published between 1993 and 2014. Twenty-three studies consisting of 38906 subjects were identified (17812 cases, 21094 controls), with zero of the four analyses performed exhibiting heterogeneity. A significant association was not found between Caucasian populations and the polymorphism or the CAD subgroup and the
polymorphism. The authors concluded that allele 719Arg may have a protective association to present CHD in all populations and the Trp719Arg polymorphism of the \textit{KIF6} gene is an important risk factor for developing MI (Ruiz-Ramos et al., 2015).

\textbf{Proprietary Testing}

\textit{Cardiovascular Risk Panels/Profiles}

Cardiovascular risk panels refer to combinations of cardiac markers that are used for the risk assessment of developing cardiovascular disease, major adverse cardiovascular events, or ischemic cerebrovascular events. Commercially available risk panels use different combinations of lipids, inflammatory, genetic, and metabolic markers. Risk panels report the results of multiple individual tests, whereas quantitative risk scores generally use proprietary algorithms to combine the results of multiple markers into one score. The clinical utility of risk panels is lacking as the impact of results on patient management is unknown.

Examples of commercially available cardiovascular risk panels include, but are not limited to:

1. Genova Diagnostics CV Health Plus™ Panel:
   - Lipid markers (LDL; total cholesterol; HDL; triglycerides; LDL size; LDL particle number; HDL size; HDL particle number; lipoprotein (a))
   - Independent risk factors (hs-CRP; fibrinogen; homocysteine; LP-PLA2)
   - Insulin Resistance Score by Lipid Fractionation (LDL size; Small LDL particle number; HDL size; Large HDL particle number; Large very low-density lipoprotein (VLDL) particle number; VLDL size)
   - A similar test is offered by Genova Diagnostics that includes the above markers as well as analysis of polymorphisms in Apo E, MTHFR, Factor II, and Factor V (Genova, 2021).

2. Cleveland HeartLab CVD Inflammation Testing Profile
   - F2-isoprostanes; oxidized LDL; hs-CRP; ADMA/SDMA; microalbumin; myeloperoxidase; Lp-PLA2 activity (HeartLab, 2020).

3. Singulex® clinical lab test panels:
   - Cardiac Function panel: SMCT™ cTnl; NT-proBNP
   - Vascular Inflammation panel: SMCT™ Endothelin; SMCT™IL-6; SMCT™ IL-17A; SMCT™ TNFα; Ferritin; homocysteine; Lp-PLA2; hs-CRP; uric acid; vitamin D; anti-CCP; rheumatoid factor; folate; vitamin B12.
   - Lipid Management panel: Total Cholesterol, LDL-C (direct), apo A-1, apo B, sdLDL, HDL-C, HDL with fractionation (HDL + HDL2 + HDL3), triglycerides, Lp(a), total
• Diabetes and Weight Management: Adiponectin, Cortisol, Cystatin C, Ferritin, GGT, Glucose, HbA1c, Insulin, Leptin, Vitamin D, Calcium, Magnesium, Phosphorus (Singulex, 2019). Singulex ceased operations as of June 2019 (360dx, 2019).

4. WellnessFX various packages:

• Basic offerings include panels with markers such as Apo A-1 and Apo-B; the basic panel comes with over 25 markers, with the “premium” panel assessing 92 markers (WellnessFX, 2021).

VI. Guidelines and Recommendations

American College of Cardiology (ACC) and the American Heart Association (AHA)

2019 ACC and AHA guidelines state that “Adults who are 40 to 75 years of age and are being evaluated for cardiovascular disease prevention should undergo 10-year atherosclerotic cardiovascular disease (ASCVD) risk estimation and have a clinician–patient risk discussion before starting on pharmacological therapy, such as antihypertensive therapy, a statin, or aspirin. In addition, assessing for other risk-enhancing factors can help guide decisions about preventive interventions in select individuals, as can coronary artery calcium scanning (Arnett et al., 2019).”

Laboratory testing was not addressed in this update.

The ACC and AHA published joint guidelines on the assessment of cardiovascular risk in asymptomatic patients in 2010 (Greenland et al., 2010), and updated in 2013 (Goff et al., 2014).

In adults between the ages of 20 and 79 who are free from CVD, the ACC/AHA state that it is reasonable to assess risk factors (smoking, hypertension, diabetes, total cholesterol, high density lipoprotein cholesterol) every four to six years so as to calculate 10-year CVD risk (Goff et al., 2014).

ACC/AHA also made the following recommendations on reclassification or contribution to risk assessment when high-sensitivity C-reactive protein (hs-CRP), apolipoprotein B (ApoB), glomerular filtration rate (GFR), microalbuminuria, family history, cardiorespiratory fitness, ankle-brachial index (ABI), carotid intima-media thickness (CIMT), or coronary artery calcium (CAC) score are considered in addition to the variables that are in the traditional risk scores:

1. If, after quantitative risk assessment, a risk-based treatment decision is uncertain, assessment of 1 or more of the following—family history, hs-CRP, ABI or CAC may be considered to inform treatment decision making.

2. CIMT is not recommended for routine measurement in clinical practice for risk assessment for a first ASCVD event.
3. The contribution to risk assessment for a first ASCVD event using ApoB, chronic kidney disease, albuminuria, or cardiorespiratory fitness is uncertain at present (Goff et al., 2014).

The 2010 guidelines contained the following statement concerning testing for Lp-PLA2: Lipoprotein-associated phospholipase A2 might be reasonable for cardiovascular risk assessment in intermediate-risk asymptomatic adults. However, the 2013 guidelines on the assessment of cardiovascular risk do not mention Lp-PLA2 testing (Goff et al., 2014; Greenland et al., 2010).

The updated guidelines do not address arterial compliance, lipoprotein-associated phospholipase, long-chain omega-3 fatty acids, 9p21 polymorphisms, KIF6 genotyping, endothelial function assessment as methods to assess initial CVD risk. The 2013 ACC/AHA guidelines on the assessment of cardiovascular risk did not address assessment of 9p21 polymorphisms or KIF6 genotyping, however, the 2010 guidelines recommended against genotype testing for “CHD risk assessment in asymptomatic adults” (Goff et al., 2014; Greenland et al., 2010).

The ACC notes cutoffs of certain biomarkers for increased ASCVD risk, which are as follows: persistently elevated, primary hypertriglyceridemia ≥175 mg/dL, ≥2 mg/L hs-CRP, ≥50 mg/dL or ≥125 nmol Lp(a), ≥130 mg/dL Apo B (corresponding to >160 mg/dL LDL-C), and <0.9 ankle-brachial index (ABI) (ACC, 2018; Grundy et al., 2019).

The ACC and AHA also released joint guidelines with the AAPA, ABC, ACPM, AGS, APhA, ASH, ASPC, NMA, and PCNA, stating that screening and management of dyslipidemia/hypercholesterolemia is recommended in adults with hypertension (defined as >130/80 mmHg) (Whelton et al., 2018).


This joint report discusses management of blood cholesterol. The report addresses treatments, populations of interest, and serum assessments of relevant cardiovascular biomarkers such as Apo B and lipoprotein A. The relevant recommendations are listed below:

The report notes that although measurement of Apo B may be “unreliable”, persistent elevation of Apo B may be considered a risk factor. The report remarks that a level of >130 mg/dL Apo B should be considered a risk-enhancing factor [of ASCVD], as it corresponds to an LDL-C level of ≥160 mg/dL.

The report also remarks that Lp(a) is considered a risk factor for ASCVD at levels of “≥50 mg/dL or ≥125 nmol/L”. However, the authors write that it should be “considered in women only in the presence of hypercholesterolemia and with the understanding that the improvement in risk prediction in adult women in a large clinical trial was minimal”.

The power of these risk factors can be seen in the “pooled cohort equation”, “the single most robust tool for estimating 10-year risk in US adults 40 to 75 years of age”. These algorithms have strong representative power for larger populations. However, a notable limitation of these
algorithms is that they are not as accurate for individuals. Hence a clinician-patient risk discussion can individualize risk status based on PCE, but with the inclusion of additional risk-enhancing factors. These additional factors may include:

- “A family history of premature ASCVD (males, age <55 y; females, age <65 y)
- Primary hypercholesterolemia (LDL-C, 160–189 mg/dL [4.1–4.8 mmol/L]; non–HDL-C 190–219 mg/dL [4.9–5.6 mmol/L])
- Metabolic syndrome (increased waist circumference, elevated triglycerides [≥150 mg/dL], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 in women mg/dL] are factors; tally of 3 makes the diagnosis)
- Chronic kidney disease (eGFR 15–59 mL/min/1.73 m2 with or without albuminuria; not treated with dialysis or kidney transplantation)
- Chronic inflammatory conditions such as psoriasis, RA, or HIV/AIDS
- History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that increase later ASCVD risk such as preeclampsia
- High-risk race/ethnicities (eg, South Asian ancestry)
- Lipid/biomarkers: Associated with increased ASCVD risk
- Persistently elevated, primary hypertriglyceridemia (≥175 mg/dL)
- Elevated high-sensitivity C-reactive protein (≥2.0 mg/L)
- Elevated Lp(a): A relative indication for its measurement is family history of premature ASCVD. An Lp(a) ≥50 mg/dL or ≥125 nmol/L constitutes a risk-enhancing factor especially at higher levels of Lp(a)
- Elevated apoB ≥130 mg/dL: A relative indication for its measurement would be triglyceride ≥200 mg/dL. A level ≥130 mg/dL corresponds to an LDL-C ≥160 mg/dL and constitutes a risk-enhancing factor
- ABI <0.9”

American Diabetes Association (ADA)

The updated ADA Standards of Medical Care in Diabetes document also includes a section focused on cardiovascular disease and risk management. Laboratory related guidelines are below:

- “In asymptomatic patients, routine screening for coronary artery disease is not recommended as it does not improve outcomes as long as atherosclerotic cardiovascular disease risk factors are treated.”
- “Consider investigations for coronary artery disease in the presence of any of the following: atypical cardiac symptoms (e.g., unexplained dyspnea, chest discomfort); signs or symptoms of associated vascular disease including carotid bruits, transient ischemic attack, stroke, claudication, or peripheral arterial disease; or electrocardiogram abnormalities.”
• “In adults not taking statins or other lipid-lowering therapy, it is reasonable to obtain a lipid profile at the time of diabetes diagnosis, at an initial medical evaluation, and every 5 years thereafter if under the age of 40 years, or more frequently if indicated.”
• “…risk scores and other cardiovascular biomarkers have been developed for risk stratification of secondary prevention patients (i.e., those who are already high risk because they have ASCVD) but are not yet in widespread use.”
• “The American College of Cardiology/American Heart Association ASCVD risk calculator (Risk Estimator Plus) is generally a useful tool to estimate 10-year risk of a first ASCVD event…The 10-year risk of a first ASCVD event should be assessed to better stratify ASCVD risk and help guide therapy, as described below.”
• “Obtain a lipid profile at initiation of statins or other lipid-lowering therapy, 4–12 weeks after initiation or a change in dose, and annually thereafter as it may help to monitor the response to therapy and inform medication adherence (ADA, 2020, 2021a).”

Also, for children and adolescents, the following recommendations were given for dyslipidemia testing:

• “Initial lipid testing should be performed when initial glycemic control has been achieved and age is ≥2 years. If initial LDL cholesterol is ≤100 mg/dL (2.6 mmol/L), subsequent testing should be performed at 9-11 years of age. Initial testing may be done with a nonfasting non-HDL cholesterol level with confirmatory testing with a fasting lipid panel.
• If LDL cholesterol values are within the accepted risk level (<100 mg/dL [2.6 mmol/L]), a lipid profile repeated every 3 years is reasonable (ADA, 2020, 2021b).”

**National Lipid Association (NLA)**

The NLA published a scientific statement for lipid measurements in the management of cardiovascular disease, and their recommendations (with evidence rating of “B” or higher) are included below:

• “It is recommended to follow up abnormal screening lipid measurements with fasting lipid measurement (Strength: IIa. Evidence: B-NR)
• LDL-C in adults ≥190 mg/dL (≥160 mg/dL in children) is recommended to be reported as possible Familial Hypercholesterolemia (Strength: I. Evidence: B-NR)
• Non-HDL-C in adults ≥220 mg/dL is recommended to be reported as possible inherited hyperlipidemia (Strength: I. Evidence: B-NR)
• Triglyceride concentration ≥500 mg/dL is recommended to be reported as severe hypertriglyceridemia (Strength: I. Evidence: B-NR)
• Lipid measurements are recommended at 3-12 months for those on a stable medication regimen (Strength: I. Evidence: B-NR)
• Lipid measurements are recommended 4-12 weeks after a change in lipid treatment (Strength: I. Evidence: B-NR)
• LDL-C measurement is recommended for screening (Strength: I. Evidence: B-NR)
• LDL-C measurement is recommended on lipid therapy (Strength: I. Evidence: B-NR)
• Non-HDL-C measurement is recommended for screening (Strength: I. Evidence: B-NR)
• Non-HDL-C measurement is recommended on lipid therapy (Strength: I. Evidence: B-NR)
• Apolipoprotein B measurement may be reasonable for initial evaluation (Strength: IIb. Evidence: B-NR)
• Apolipoprotein B measurement is reasonable on lipid therapy (Strength: IIa. Evidence: B-NR)
• Apolipoprotein B measurement is recommended to facilitate diagnosis of Familial Dysbetalipoproteinemia and Familial Combined Hyperlipidemia (Strength: IIb. Evidence: B-NR)
• Lipoprotein (a) measurement is reasonable for initial evaluation in those with premature ASCVD, family history of premature ASCVD or of elevated Lp(a), history of LDL-C >190 mg/dL or suspected FH, or those with very high ASCVD risk (Strength: IIa. Evidence: B-NR)
• Lipoprotein (a) measurement may be reasonable on lipid therapy to determine those who may benefit from PCSK9 therapy who are already on maximal dose statin therapy ± ezetimibe, whose LDL-C remains above 70 mg/dl (Strength: IIb. Evidence: B-NR)"

Wilson et al. (2019) published a scientific statement to provide an update on the use of lipoprotein A [Lp(a)] in the clinical setting, particularly for atherosclerotic cardiovascular disease (ASCVD).

The Association lists the following recommendations for Lp(a) testing in clinical practice:

For adults over 20 years old, “Measurement of Lp(a) is reasonable to refine risk assessment for ASCVD events in:
• Individuals with a family history of first-degree relatives with premature ASCVD (<55 y[ears] of age in men, 65 y of age in women)
• Individuals with premature ASCVD (males aged <55 y and females aged <65 y), particularly in the absence of traditional risk factors
• Individuals with primary severe hypercholesterolemia (LDL ≥190 mg/dL) or suspected FH [familial hypercholesterolemia]
• Individuals at very high** risk of ASCVD to better define those who are more likely to benefit from PCSK9 inhibitor therapy.”

** Very high risk is defined as “Individuals with a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk conditions.”

The guidelines further remark that “Measurement of Lp(a) may be reasonable with:
• Intermediate (7.5%–19.9%) 10-y ASCVD risk when the decision to use a statin is uncertain, to improve risk stratification in primary prevention.
• Borderline (5%–7.4%) 10-y ASCVD risk when the decision to use a statin is uncertain, to improve risk stratification in primary prevention.
• Less-than-anticipated LDL-C lowering, despite good adherence to therapy.
• A family history of elevated Lp(a).
• Calcific valvular aortic stenosis.
• Recurrent or progressive ASCVD, despite optimal lipid-lowering therapy.”
Finally, the guidelines list recommendations for “youth” (<20 years old), stating that “Measurement of Lp(a) may be reasonable with:

- Clinically suspected or genetically confirmed FH.
- Individuals with a family history of first-degree relatives with premature ASCVD (<55 y of age in men, 65 y of age in women)
- An unknown cause of ischemic stroke
- A parent or sibling found to have an elevated Lp(a) (Wilson et al., 2019).”

**Centers for Disease Control and Prevention (CDC)**

The CDC highlights the importance of cardiovascular disease biomarkers and has developed a reference laboratory and clinical standardization program to provide reference measurements for HDL-C, LDL-C, TG and total cholesterol (TC). The accuracy of the labs that analyze these biomarkers is also monitored by the CDC (CDC, 2017a).

The CDC notes that several health conditions increase the risk of heart disease including smoking, diabetes mellitus, obesity, high blood pressure, excessive alcohol use, physical inactivity, and unhealthy blood cholesterol levels. It is stated that “High blood cholesterol usually has no signs or symptoms. The only way to know whether you have high cholesterol is to get your cholesterol checked. Your health care team can do a simple blood test, called a “lipid profile,” to measure your cholesterol levels (CDC, 2019).”

The CDC has also developed the Lipids Standardization Program (LSP). This program ensures that the measurements reported in research studies and clinical laboratories are accurate. Blinded samples traceable to the CDC Reference Laboratory are provided to participants. The samples will be measured for total cholesterol (TC), glycerides (TG), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-I (apo A-I), and apolipoprotein B (apo B). LSP participants report their results from the provided samples back to the CDC where these results are then analyzed; if results are accurate, those laboratories receive a certificate and are considered CDC-certified (CDC, 2017b).

**American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE)**

The 2017 AACE and ACE Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease recommend:

- Screening guidelines for dyslipidemia vary by age group;
- Although ASCVD risk in young adults is low, adults older than 20 years should be evaluated for dyslipidemia every 5 years as part of a global risk assessment
- Middle-aged individuals (Men 45-65 years, Women 55-65 years) should be screened for dyslipidemia at least every 1 to 2 years.
- All individuals with diabetes should be screened with a lipid profile at the time of diagnosis and annually thereafter. Some individuals with diabetes can be screened less frequently
based on clinical considerations

- Annual screen for dyslipidemia for adults over 65 is recommended
- In children at risk for FH (e.g., family history of premature cardiovascular disease or elevated cholesterol), screening should be at 3 years of age, between 9 and 11, and at age 18
- Screen adolescents older than 16 years every 5 years or more frequently if they have ASCVD risk factors, have overweight or obesity, have other elements of the insulin resistance syndrome, or have a family history of premature ASCVD
- Direct measurement of LDL-C should be used to assess LDL-C in certain high-risk individuals, such as those with fasting TG concentrations greater than 250 mg/dL or those with diabetes or known vascular disease
- Apolipoproteins, Apo B and/or an apo B/apo A1 ratio calculation and evaluation may be useful in at-risk individuals.
- hsCRP is recommended to stratify ASCVD risk in individuals with a standard risk assessment that is borderline, or in those with an intermediate or higher risk with an LDL-C concentration <130 mg/dL.
- Lp-PLA2 measurement, is recommended when it is necessary to further stratify an individual’s ASCVD risk, especially in the presence of hsCRP elevations.
- The routine measurement of homocysteine, uric acid, plasminogen activator inhibitor-1, or other inflammatory markers is not recommended because the benefit of doing so is not sufficiently proven.
- Coronary artery calcification (CAC) measurement has been shown to be of high predictive value and is useful in refining risk stratification
- Carotid intima media thickness (CIMT) may be considered to refine risk stratification (Jellinger et al., 2017).

The AACE/ACE published an updated algorithm in 2020. This algorithm focuses on “management of dyslipidemia and prevention of cardiovascular disease” and “complements” the above guidelines, but includes information not available in 2017. Their relevant recommendations are listed below:

The guideline lists Apo B, LDL, Lp(a), and hs-CRP as biomarkers that may be “considered” in assessment of ASCVD risk for patients. The guideline also remarks that “measurement of apo B is useful in assessing the success of lipid-lowering therapy, since apo B may remain above goal after achieving the LDL-C goal.” Apo B is listed as a component of treatment goals, alongside LDL-C, Non-HDL-C, and TG [triglycerides].

The guideline recommends “considering” measurement of Lp(a) (lipoprotein A) in the following settings:

- “All patients with clinical ASCVD, especially premature or recurrent ASCVD despite
LDL-C lowering;

- Individuals with a family history of premature ASCVD and/or increased Lp(a);
- Individuals with South Asian or African ancestry, especially with a family history of ASCVD or increased Lp(a);
- Individuals with a 10-year ASCVD risk ≥10% (primary prevention setting), in order to stratify risk;
- Patients with a personal or family history of aortic valve stenosis;
- Patients with refractory elevations of LDL-C despite aggressive LDL-C-lowering therapy (i.e., statin resistance)” (AACE, 2021).

The AACE also published a “consensus statement” on the “comprehensive type 2 diabetes management algorithm”. The guideline includes a set of PowerPoint slides at the bottom, which recommend measuring Lp(a) in the following settings: presence of family history of premature ASCVD and/or increased Lp(a), and all patients with premature or recurrent ASCVD despite LDL-C lowering (Garber et al., 2020).

**2016, 2019 European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemias**

The ESC published 2021 guidelines on cardiovascular disease prevention in clinical practice. A summary of the new recommendations relevant to CVD risk assessment are included below (Visseren et al., 2021):
ESC and EAS guidelines give the following 2019 recommendations:

- “Lp(a) measurement should be considered at least once in each adult person’s lifetime to identify those with very high inherited Lp(a) levels >180 mg/dL (>430 nmol/L) who may
have a lifetime risk of ASCVD equivalent to the risk associated with heterozygous familial hypercholesterolemia.

- “Persons with documented ASCVD, type 1 or type 2 DM (T1DM and T2DM, respectively), very high levels of individual risk factors, or chronic kidney disease (CKD) are generally at very-high or high total CV risk. No risk estimation models are needed for such persons…”

- ApoB analysis is recommended for risk assessment, particularly in people with high TG, DM, obesity or metabolic syndrome, or very low LDL-C. It can be used as an alternative to LDL-C, if available, as the primary measurement for screening, diagnosis, and management, and may be preferred over non-HDL-C in people with high TG, DM, obesity, or very low LDL-C.

- CAC score assessment with CT may be helpful in reaching decisions about treatment in people who are at moderate risk of ASCVD. Obtaining such a score may assist in discussions about treatment strategies in patients where the LDL-C goal is not achieved with lifestyle intervention alone and there is a question of whether to institute LDL-C-lowering treatment. Assessment of arterial (carotid or femoral) plaque burden on ultrasonography may also be informative in these circumstances (Mach et al., 2019).”

Total cholesterol may be used to estimate total cardiovascular risk. LDL-C is recommended to be used as the primary lipid analysis for diagnosis, management, screening, and risk estimation. HDL-C and Non-HDL-C are also strong, independent risk factors (Catapano et al., 2016).

Apo B, Lp(a), Apo B/Apo A-I, and Non-HDL-C/HDL-C may all be used as alternative markers for cardiovascular risk. The guidelines note that measuring Apo B and Apo A-I is convenient, accurate, does not require fasting, and is not susceptible to TG levels. The guidelines also recommend against routine measurement of Apo C-III as its use is unknown (Catapano et al., 2016).

**European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)**

This joint guideline was published for “diabetes, pre-diabetes, and cardiovascular diseases”. Their relevant recommendations are listed below:

- Routine assessment of novel biomarkers is not recommended for CV risk stratification.

The guideline noted that “the addition of circulating biomarkers for CV risk assessment has limited clinical value” and stated that “in patients with DM [diabetes mellitus] without known CVD, measurement of C-reactive protein or fibrinogen (inflammatory markers) provides minor incremental value to current risk assessment”. The guideline also noted high-sensitivity cardiac troponin T as not adding incremental “discriminative power” for patients with DM without known CVD (Cosentino et al., 2020), although elevated high-sensitivity cardiac troponin T was noted as an independent predictor of renal decline and CV events in patients with type 1 diabetes (Cosentino et al., 2020)
Endocrine Society (ES)

This guideline was published with the intent to assess and treat dyslipidemia in patients with endocrine disorders. Their relevant recommendations are listed below:

- “In adults with endocrine disorders, we recommend a lipid panel for the assessment of triglyceride levels and for calculating low-density lipoprotein cholesterol.”

- “In adults with endocrine disorders, we recommend conducting a cardiovascular risk assessment by evaluating traditional risk factors, including the calculation of 10-year atherosclerotic cardiovascular disease risk using a tool such as the Pooled Cohort Equations.”

The guideline also remarks that certain “advanced” lipid testing (assessment of markers such as Apo B, lipid fractionation, and Lp(a)) may be helpful in “characterizing” lipid abnormalities, but “add little” to risk prediction beyond the standard lipid profile. The guideline also notes that genetic tests for risk stratification may “modestly” improve risk prediction, but are not available in clinical practice. The guideline does remark that Apo B and non-HDL cholesterol should be considered “risk-enhancing” factors.

The guideline goes on to discuss Lp(a), noting that the marker can be helpful in assessing familial risk, but adds “little” in terms of global risk assessment across the general population. The guideline acknowledges other evidence supporting Lp(a)’s use as a marker to manage treatment. Other serum biomarkers and biomarker panels were also considered to add “little” to global risk assessment. Finally, the guideline recommends the use of hs-CRP as a “risk-enhancing factor that may drive more aggressive treatment or the need for advanced risk assessment” (Newman et al., 2020).

Rosenzweig et al. (2019) published on the Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk. A summary of the recommendations is included below (Rosenzweig et al., 2019):

- “In individuals aged 40–75 years in the office setting, we suggest providers screen for all five components of metabolic risk at the clinical visit. The finding of at least three components should specifically alert the clinician to a patient at metabolic risk (at higher
risk for atherosclerotic cardiovascular disease and type 2 diabetes mellitus).

- In individuals aged 40-75 years in the office setting who do not yet have atherosclerotic cardiovascular disease or type 2 diabetes mellitus and already have at least one risk factor, we advise screening every 3 years for all five components of metabolic risk as part of the routine clinical examination.

- To establish metabolic risk in the general population, we recommend that clinicians measure waist circumference as a routine part of the clinical examination.

- In individuals previously diagnosed with prediabetes, we suggest testing at least annually for the presence of overt type 2 diabetes mellitus.

- We recommend that all individuals at metabolic risk in the office setting have their blood pressure measured annually and, if elevated, at each subsequent visit.

- For individuals with elevated blood pressure above 130 mmHg systolic and/or 80 mmHg diastolic who are not documented as having a history of hypertension, we recommend confirmation of elevated blood pressure on a separate day within a few weeks or with a home blood pressure monitor.”

Components of “metabolic risk” are defined as:

- elevated blood pressure
- increased waist circumference
- elevated fasting triglycerides
- low high-density lipoprotein-cholesterol, and
- elevated glycemia.

American Society for Clinical Pathology

The ASCP recommends against routinely ordering expanded lipid panels (such as particle sizing or nuclear magnetic resonance) as screening for cardiovascular disease (ASCP, 2016).

Scottish Intercollegiate Guidelines Network

SIGN recommends that patients with established cardiovascular disease, stage 3 chronic kidney disease, micro or macro albuminuria, familial hypercholesterolemia, diabetes and are older than 40 should be considered high risk for cardiovascular events. Diabetes patients under 40 but who have had the disease for 20 years, target organ damage, or other cardiovascular risk factors are also considered high risk.

A cardiovascular risk assessment should be offered to patients 40 or older or any patient with a first degree relative with premature atherosclerotic CVD or familial dyslipidemia, at least every five years.

Asymptomatic individuals should be considered high risk if they are evaluated at a ≥20% risk of a first cardiovascular event within ten years.
A lipid profile should include total cholesterol, HDL, triglycerides, and should not be taken during intercurrent illness (SIGN, 2017).

National Institute for Health and Care Excellence (NICE)

A baseline lipid profile should be taken before treatment. This should include total cholesterol, HDL cholesterol, non-HDL, and triglyceride levels. Total and HDL cholesterol should be measured for best estimate of CVD risk.

Omega-3 compounds have “no evidence” to help prevent CVD and NICE recommends against distribution of these compounds for CVD treatment (NICE, 2016).

US Preventive Services Task Force (USPSTF)

The USPSTF Task Force Recommendations include periodic assessment of cardiovascular risk factors from ages 40 to 75 years, including measurement of total cholesterol, LDL-C, and HDL-C levels. The optimal intervals for cardiovascular risk assessment are uncertain. Based on other guidelines and expert opinion, reasonable options include annual assessment of blood pressure and smoking status and measurement of lipid levels every 5 years. Shorter intervals may be useful for persons at higher risk, and longer intervals are appropriate for persons who are regularly at average risk (Bibbins-Domingo et al., 2017).

The USPSTF found insufficient evidence that screening for dyslipidemia in younger adults influences cardiovascular outcomes, and no studies that evaluated the effects of screening vs no screening, treatment vs no treatment, or delayed vs earlier treatment in adults in this age group. Thus, the USPSTF recommends neither for nor against screening for dyslipidemia in this age group. The USPSTF also noted there was insufficient evidence to assess the balance of benefits and harms of screening for dyslipidemia in children and adolescents (Chou et al., 2016).

The USPSTF states that “current evidence is insufficient to assess the benefits and harms of adding ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) level, or coronary artery calcium (CAC) score to traditional risk assessment for cardiovascular disease (CVD) in asymptomatic adults to prevent CVD events (USPSTF, 2018).” However, the USPSTF recommends screening for abnormal blood glucose for adults aged 40-70 who are overweight or obese (USPSTF, 2015).

The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for primary hypertension in asymptomatic children and adolescents to prevent subsequent cardiovascular disease (Moyer, 2013). A 2020 recommendation statement by the USPSTF confirmed that the current evidence is insufficient to assess the balance of benefits and harms of screening for high blood pressure in children and adolescents (in general) (USPSTF, 2020). In adults, however, The USPSTF recommends screening for hypertension (persons 18 years or older) with office blood pressure measurement (OBPM). The USPSTF recommends obtaining blood pressure measurements outside of the clinical setting for diagnostic confirmation before starting treatment (USPSTF, 2021).
Finally, screening for obesity in children 6 years or older is recommended (Bibbins-Domingo et al., 2017).

**Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE)**

C-CHANGE recommends a cardiovascular risk assessment for adults from 40-75 years old every five years. A risk assessment may also be done when a patient’s expected risk changes.

C-CHANGE recommends plasma lipid screening for adults older than 40 years, as well as lipid screening if a patient has any of the following conditions:

- Clinical evidence of atherosclerosis
- Abdominal aortic aneurysm
- Diabetes mellitus
- Arterial hypertension
- Current cigarette smoking
- Stigmata of dyslipidemia (arcus cornealis xanthelasma or xanthoma)
- Family history of cardiovascular disease‡
- Chronic kidney disease§
- Obesity (BMI ≥ 30 kg/m²)
- Inflammatory disease
- HIV infection
- Erectile dysfunction
- Chronic obstructive pulmonary disease
- Hypertensive diseases of pregnancy

‡Men aged < 55 yr and women aged < 65 yr of age in first-degree relative
§Chronic kidney disease: eGFR < 60 mL/min/1.73 m² or ACR > 3 mg/mmol for at least 3-mo duration (Tobe et al., 2018)

**Canadian Cardiovascular Society (CCS)**

The CCS published updated recommendations on the management of dyslipidemia for the prevention of cardiovascular disease in adults. A summary of the society’s recommendations that are relevant to CVD risk assessment is provided below:

- “Among women whose pregnancy was complicated by the hypertensive disorders of pregnancy -- gestational hypertension and/or preeclampsia -- or a preterm birth before 34 weeks’ gestation, a stillbirth and/or a placental abruption, we recommend screening with a comprehensive lipid panel at least 12 weeks postpartum. These women have a higher risk
of premature CVD and stroke within 10-15 years after the affected pregnancy (Strong Recommendation, Moderate Quality Evidence).

- To assist with decisions about initiating lipid-lowering pharmacotherapy in a nonpregnant woman who had one or more of these pregnancy complications, we recommend referral to a specialized postpartum cardiovascular health clinic or specialized lipid clinic, if locally available. If such resources are not locally available, we recommend using standard risk assessment tools to decide about lipid-lowering pharmacotherapy. However, when interpreting their 10-year CVD risk using a risk calculator, it is important to note that most women in this group will be found to have a low calculated absolute risk of CVD, short-term, which may give a false sense of reassurance to both the patient and her health care provider. (Weak Recommendation; Low-Quality Evidence).

- For any patient with triglycerides > 1.5mM, use non-HDL-C or apoB instead of LDL-C as the preferred lipid parameter for initial screening and treatment target (< 2.6 mM for non-HDL-C or < 0.8 g/L for apoB) in intermediate or high risk individuals (Strong Recommendation, High-Quality Evidence).

- We recommend measuring lipoprotein (a) level once in a person’s lifetime as a part of the initial lipid screening (Strong Recommendation; High-Quality Evidence).

- We suggest that CAC [coronary artery calcium] screening using computed tomography imaging may be considered for asymptomatic adults 40 years or older and at intermediate risk (FRS 10%-20%) for whom treatment decisions are uncertain (Weak Recommendation, Moderate-Quality Evidence).

- We recommend that CAC screening using computed tomography imaging not be undertaken for: (1) high-risk individuals; (2) patients receiving statin treatment; or (3) most asymptomatic, low-risk adults (Strong Recommendation; Moderate-Quality Evidence).

- We suggest that CAC screening may be considered for a subset of low-risk individuals 40 years or older, in addition to identifying known genetic causes of ASCVD such as elevated Lp(a) or Familial hypercholesterolemia) in those with a family history of premature CVD (men younger than 55 years; women younger than 65 years) (Weak Recommendation; Low-Quality Evidence).

As per the 2016 guidelines, a CV risk assessment is recommended for adults 40-75 every five years, or when a patient’s expected risk status changes.

Nonfasting lipid and lipoprotein testing is recommended during the CV risk assessment. The CCS notes that since LDL-C is still the most familiar to clinicians, it is still recommended, but the society “anticipates a shift to preferential use of non-HDL-C or Apo B in the future”. The CCS recommends non-HDL-C and Apo B as alternate targets to LDL-C.

Lp(a) “might aid” risk assessment for subjects with an intermediate Framingham Risk Score or
family history of premature CAD. Repeat measures of this biomarker are not indicated (CCS, 2016).

2014 HIV Medicine Association of the Infectious Diseases Society of America

HIV-infected patients commonly develop dyslipidemia after starting antiretroviral therapy (ART). The lipid abnormalities developed in HIV-infected patients are associated with increased cardiovascular risk. HIV Medicine Association of the Infectious Diseases Society of America have updated their guidelines in 2013 to include a new section on metabolic comorbidities. They recommend obtaining a fasting lipid profile prior to and within 1-3 months after starting ART and every 6-12 months in all patients.

The Association also notes that HbA1c may be tested or used for screening and states that a lower cutoff of 5.8% for diabetes may be used for patients on ART instead of the higher 6.5%. Finally, the Association recommends measuring HbA1c every six months in patients with diabetes (Aberg et al., 2014).

American Heart Association Statements (AHA)

A policy statement from the AHA on genetics and cardiovascular disease stated “although robust GWAS [genome wide association studies] evidence exists linking common variants to complex CVD, studies are not yet available to inform the clinical benefit of providing such genetic information to patients (Ashley et al., 2012).”

Another AHA statement on evaluating genetic variations in association with cardiovascular risk was released in 2017. The statement notes that Corus CAD is “a clinically available diagnostic test that has been evaluated, has been deemed to be valid and useful, and accordingly is covered by many insurers.” The AHA further states that Corus CAD has met many of the National Cancer Institute’s set of 30 criteria (Musunuru et al., 2017).

U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD)

The United States VA and DoD published a joint guideline regarding management of dyslipidemia for reducing CVD risk in adults. Their relevant recommendations are listed below:

- “For primary prevention in patients over age 40 and not on statin therapy who have not developed new cardiovascular risk factors (e.g., diabetes, hypertension, tobacco use), we suggest against offering a cardiovascular disease risk assessment more frequently than every five years.”

- “For primary prevention in patients not on statin therapy, we suggest against routinely ordering a lipid panel more frequently than every 10 years.”

- “For cardiovascular risk assessment in primary prevention, we suggest using a 10-year risk calculator.”
• “We suggest against the routine use of coronary artery calcium testing.”

• “We suggest against the routine use of additional risk markers (e.g., high-sensitivity C-reactive protein, ankle-brachial index, coronary artery calcium) when assessing cardiovascular risk.”

The guideline also remarks that several other markers, such as “coronary artery calcium (CAC), high-sensitivity C-reactive protein, ankle–brachial index, and apolipoprotein evaluations” have been proposed as useful tools to determine risk. However, these markers have been deemed “limited in further refining risk”. Although CAC was considered to best of the markers listed, the guideline still recommended against routine CAC testing.

The guideline also recommends against “routine lipid level testing for risk assessment and monitoring, unless it is specifically intended to guide decision making” (O’Malley et al., 2020).

2016 European Society of Cardiology (ESC) and Other Societies on Cardiovascular Disease Prevention in Clinical Practice

In 2016, the Sixth Joint Task Force of the ESC and Other Societies on Cardiovascular Disease Prevention in Clinical Practice published guidelines on cardiovascular disease prevention in clinical practice. The Task Force recognized that genetic screening could be useful in some conditions such as familial hypercholesterolemia. However, they do not recommend genetic screening in general population. According to the Task Force, there is no consensus regarding which genes and their corresponding single nucleotide polymorphisms that should be included in a genetic risk score. They also state that the available data is currently insufficient to make any recommendations regarding genetic testing for prediction of cardiovascular risk and/or effectiveness of statin therapy. They do not recommend the use of genetic markers for the prediction of CVD and by extension cannot recommend for or against any commercial tests (Piepoli et al., 2016).

Routine assessment of circulating or urinary biomarkers is not recommended for CVD risk stratification. The Task Force states that there is conflicting data on the utility of these biomarkers (such as hsCRP, various apolipoproteins, etc.) and that the overall contributions of these biomarkers to the current methods of risk assessment are minor. Furthermore, the degree to which these biomarkers do influence a patient’s total CVD risk is highly variable (Piepoli et al., 2016).

The Task Force recommends repeating risk assessment every 5 years, and more often for higher risk patients. However, the Task Force only recommends this screening procedure for men >40 years and women >50 years or post-menopausal, declaring that “systematic risk assessment in men <40 years and women <50 with no known CV risk factors is not recommended” due to low cost effectiveness (Piepoli et al., 2016).

VII. Applicable State and Federal Regulations
DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

A. Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

B. Centers for Medicare & Medicaid Services (CMS)


VIII. Applicable CPT/HCPCS Procedure Codes

<table>
<thead>
<tr>
<th>CPT</th>
<th>Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>80061</td>
<td>Lipid panel This panel must include the following: Cholesterol, serum, total (82465) Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478)</td>
</tr>
<tr>
<td>81402</td>
<td>Molecular pathology procedure, Level 3 (eg, &gt;10 SNPs, 2-10 methylated variants, or 2-10 somatic variants [typically using non-sequencing target variant analysis], immunoglobulin and T-cell receptor gene rearrangements, duplication/deletion variants of 1 exon, loss of heterozygosity [LOH], uniparental disomy [UPD])</td>
</tr>
<tr>
<td>81403</td>
<td>Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of &gt;10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)</td>
</tr>
<tr>
<td>81404</td>
<td>Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)</td>
</tr>
<tr>
<td>81405</td>
<td>Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)</td>
</tr>
<tr>
<td>81406</td>
<td>Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)</td>
</tr>
<tr>
<td>Code</td>
<td>Procedure Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>81407</td>
<td>Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of &gt;50 exons, sequence analysis of multiple genes on one platform)</td>
</tr>
<tr>
<td>81408</td>
<td>Molecular pathology procedure, Level 9 (eg, analysis of &gt;50 exons in a single gene by DNA sequence analysis)</td>
</tr>
<tr>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
<tr>
<td>81493</td>
<td>Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score Proprietary test: Corus®CAD</td>
</tr>
<tr>
<td></td>
<td>Lab/Manufacturer: CardioDx, Inc.</td>
</tr>
<tr>
<td>81599</td>
<td>Unlisted multianalyte assay with algorithmic analysis</td>
</tr>
<tr>
<td>82172</td>
<td>Apolipoprotein, each</td>
</tr>
<tr>
<td>82465</td>
<td>Cholesterol, serum or whole blood, total</td>
</tr>
<tr>
<td>82610</td>
<td>Cystatin C</td>
</tr>
<tr>
<td>83090</td>
<td>Homocysteine</td>
</tr>
<tr>
<td>83695</td>
<td>Lipoprotein (a)</td>
</tr>
<tr>
<td>83698</td>
<td>Lipoprotein-associated phospholipase A2 (Lp-PLA2)</td>
</tr>
<tr>
<td>83700</td>
<td>Lipoprotein, blood; electrophoretic separation and quantitation</td>
</tr>
<tr>
<td>83701</td>
<td>Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (eg, electrophoresis, ultracentrifugation)</td>
</tr>
<tr>
<td>83704</td>
<td>Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed</td>
</tr>
<tr>
<td>83718</td>
<td>Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol)</td>
</tr>
<tr>
<td>83719</td>
<td>Lipoprotein, direct measurement; VLDL cholesterol</td>
</tr>
<tr>
<td>83721</td>
<td>Lipoprotein, direct measurement; LDL cholesterol</td>
</tr>
<tr>
<td>83722</td>
<td>Lipoprotein, direct measurement; small dense LDL cholesterol</td>
</tr>
<tr>
<td>83880</td>
<td>Natriuretic peptide</td>
</tr>
<tr>
<td>84478</td>
<td>Triglycerides</td>
</tr>
<tr>
<td>84484</td>
<td>Troponin, quantitative</td>
</tr>
<tr>
<td>84512</td>
<td>Troponin, qualitative</td>
</tr>
<tr>
<td>84999</td>
<td>Unlisted chemistry procedure</td>
</tr>
<tr>
<td>85384</td>
<td>Fibrinogen; activity</td>
</tr>
<tr>
<td>85415</td>
<td>Fibrinolytic factors and inhibitors; plasminogen activator</td>
</tr>
<tr>
<td>86141</td>
<td>C-reactive protein; high sensitivity (hsCRP)</td>
</tr>
<tr>
<td>0052U</td>
<td>Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation Proprietary test: VAP Cholesterol Test</td>
</tr>
<tr>
<td></td>
<td>Lab/Manufacturer: VAP Diagnostics Laboratory, Inc</td>
</tr>
</tbody>
</table>
| 0308U  | Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for obstructive CAD }
IX. Evidence-based Scientific References


ADA. (2020). Standards of Medical Care in diabetes—2020. https://care.diabetesjournals.org/content/43/Supplement_1


of statin trials. *J Am Coll Cardiol, 64*(5), 485-494. [https://doi.org/10.1016/j.jacc.2014.02.615]


CDC. (2017a). *Cardiovascular Disease Biomarker Standardization Programs.* [https://www.cdc.gov/labstandards/cvd.html]


Reduced Ejection Fraction. *J Am Coll Cardiol, 74*(9), 1205-1217. 
https://doi.org/10.1016/j.jacc.2019.06.055

https://doi.org/10.4158/ep171764.appgl

https://doi.org/10.1373/clinchem.2015.253757

https://doi.org/10.3109/09546634.2010.546831

https://doi.org/10.3109/09546634.2010.546831

https://doi.org/10.15252/emmm.201506174

https://doi.org/10.30773/pi.2019.0063

https://doi.org/10.1007/s40273-019-00820-6


https://doi.org/10.2215/cjn.07320619

https://doi.org/10.1001/jamadermatol.2015.3091


Virani Salim, S., Alonso, A., Benjamin Emelia, J., Bittencourt Marcio, S., Callaway Clifton, W., Carson April, P., Chamberlain Alanna, M., Chang Alexander, R., Cheng, S., Delling...


